Scott Antonia is an Oncology physician. OpenAlex indexes 542 publications with 77,837 citations (h-index 95); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Mdc 44
Tampa, FL 336129416
Telephone
813-745-4673Registry record last updated 5 Feb 2014.
Clinical trials
- C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
Sponsor: AbelZeta Inc.
- A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
Sponsor: Eziafa Oduah, MD, PhD, MPH
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
- ABBVIE INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
7 NIH research awards on record, funded 1994–2022 per NIH RePORTER. The latest:
- Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
H. Lee Moffitt Cancer Ctr & Res Inst
FY2022$591,459U01CA232382 - Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
H. Lee Moffitt Cancer Ctr & Res Inst
FY2021$756,968U01CA232382 - Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
H. Lee Moffitt Cancer Ctr & Res Inst
FY2020$603,529U01CA232382
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Journal of Clinical Oncology
2022 - Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Journal of Thoracic Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”